China phase 1 trial: gum stem cells improve Type 1 diabetes in 55% of patients

A randomized phase 1 trial in Shanghai and Guangzhou reports that gingival mesenchymal stem cell therapy improved Type 1 diabetes in 55% of treated patients, with one patient achieving full insulin independence. The findings are preliminary and based on a small cohort, with long-term efficacy and safety unproven. This marks a notable early-stage advance in regenerative medicine for diabetes, though it does not yet alter clinical practice.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works